Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis

Immix Biopharma, Inc. ((IMMX)) announced an update on their ongoing clinical study.

Immix Biopharma, Inc. is collaborating on a Phase 1b/2 clinical study titled ‘Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis.’ The study aims to assess the safety and efficacy of NXC-201 in patients suffering from relapsed or refractory light chain amyloidosis (AL), a rare and serious condition. This research is significant as it explores a potential new treatment option for a challenging disease.

The intervention being tested is NXC-201 CAR-T, a biological treatment involving autologous T cells modified with a chimeric antigen receptor (CAR) targeting human BCMA. This innovative approach is designed to enhance the body’s immune response against amyloidosis.

The study employs an open-label, single-arm design with sequential dose escalation. It involves two cohorts receiving different doses of CAR-positive T cells, followed by a dose expansion phase. There is no masking, and the primary purpose is treatment-focused.

The study began on October 14, 2023, and is currently recruiting participants. The primary completion and estimated overall completion dates are yet to be announced, with the last update recorded on July 7, 2025. These timelines are crucial for tracking progress and anticipating results.

This clinical update could influence Immix Biopharma’s stock performance positively, as successful trials may enhance investor confidence and market position. The study’s progress also holds implications for competitors in the biotech industry, potentially setting a new benchmark in amyloidosis treatment.

The study is ongoing, with further details available on the ClinicalTrials portal.